Pharmacyclics, Inc. (PCYC) Posts Q2 Loss of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Big Beat for Pharmacyclics' (PCYC) Imbruvica - Baird
August 1, 2014 7:18 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) following Q2 results with Imbruvica putting up a big beat.
"We believe the substantial top-line beat will result in broad increases in consensus estimates as well as a... More
WallachBeth Capital Upgrades Pharmacyclics (PCYC) to Buy
August 1, 2014 6:52 AM EDTWallachBeth Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Hold to Buy.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $120.44 yesterday.
... More